Drugs / TriMix-DC
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01066390 | Dec 2009 → Nov 2013 | melanoma | Bart Neyns | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01302496 | Feb 2011 → Oct 2013 | melanoma | Bart Neyns | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TriMix-DC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01302496 ↗ |
| Known as | TriMixDC-MEL | “Autologous monocyte-derived dendritic cells (DCs) electroporated with synthetic messenger RNA (mRNA) encoding a CD40 ligand, a constitutively active Toll-like receptor 4 and...” PMID 23904461 ↗ Jul 2013 |
| Modality | Vaccine | “dendritic cell-based mRNA vaccination” PMID 32114500 ↗ Feb 2020 |
| Route | Intravenous | “combined intradermal (id) and intravenous (iv) administrations” PMID 23904461 ↗ Jul 2013 |